{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:10:28Z","timestamp":1793171428228,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Campus Stiftung Lindenhof Bern","award":["Bonel_21-01_Netz_AFF"],"award-info":[{"award-number":["Bonel_21-01_Netz_AFF"]}]},{"name":"University of Bern"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1007\/s00198-023-06863-y","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:02:00Z","timestamp":1690329720000},"page":"1961-1973","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-8199","authenticated-orcid":false,"given":"Judith","family":"Everts-Graber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Bonel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8123-0438","authenticated-orcid":false,"given":"Brigitta","family":"Gahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HansJ\u00f6rg","family":"H\u00e4uselmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ueli","family":"Studer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Rudolf","family":"Ziswiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8098-6567","authenticated-orcid":false,"given":"Stephan","family":"Reichenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0739-5562","authenticated-orcid":false,"given":"Thomas","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"issue":"3","key":"6863_CR1","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ (2016) Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med 374(3):254\u2013262. https:\/\/doi.org\/10.1056\/NEJMcp1513724","journal-title":"N Engl J Med"},{"issue":"3","key":"6863_CR2","doi-asserted-by":"publisher","first-page":"dgaa048","DOI":"10.1210\/clinem\/dgaa048","volume":"105","author":"D Shoback","year":"2020","unstructured":"Shoback D, Rosen CJ, Black DM et al (2020) Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. J Clin Endocrinol Metabol 105(3):dgaa048. https:\/\/doi.org\/10.1210\/clinem\/dgaa048","journal-title":"J Clin Endocrinol Metabol"},{"issue":"9","key":"6863_CR3","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S (2008) Bisphosphonates: Mechanism of action and role in clinical practice. Mayo Clin Proc 83(9):1032\u20131045. https:\/\/doi.org\/10.4065\/83.9.1032","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"6863_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","volume":"48","author":"R Baron","year":"2011","unstructured":"Baron R, Ferrari S, Russell RGG (2011) Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone 48(4):677\u2013692. https:\/\/doi.org\/10.1016\/j.bone.2010.11.020","journal-title":"Bone"},{"key":"6863_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Sodal M et al (2017) Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"issue":"1","key":"6863_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1359\/jbmr.090716","volume":"25","author":"DL Kendler","year":"2010","unstructured":"Kendler DL, Roux C, Benhamou CL et al (2010) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Min Res 25(1):72\u201381. https:\/\/doi.org\/10.1359\/jbmr.090716","journal-title":"J Bone Min Res"},{"issue":"8","key":"6863_CR7","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1002\/jbmr.81","volume":"25","author":"E Seeman","year":"2010","unstructured":"Seeman E, Delmas PD, Hanley DA et al (2010) Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res 25(8):1886\u20131894. https:\/\/doi.org\/10.1002\/jbmr.81","journal-title":"J Bone Miner Res"},{"issue":"1","key":"6863_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1359\/jbmr.0809010","volume":"24","author":"JP Brown","year":"2009","unstructured":"Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 24(1):153\u2013161. https:\/\/doi.org\/10.1359\/jbmr.0809010","journal-title":"J Bone Miner Res"},{"issue":"4","key":"6863_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1742-1241.2011.02806.x","volume":"66","author":"T Lin","year":"2012","unstructured":"Lin T, Wang C, Cai X-Z et al (2012) Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: A meta-analysis. Int J Clin Pract 66(4):399\u2013408. https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02806.x","journal-title":"Int J Clin Pract"},{"issue":"8","key":"6863_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in Postmenopausal Women with Low Bone Mineral Density. New Engl J Med 354(8):821\u201331. https:\/\/doi.org\/10.1056\/NEJMoa044459","journal-title":"New Engl J Med"},{"issue":"1","key":"6863_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00198-019-05233-x","volume":"31","author":"PD Miller","year":"2020","unstructured":"Miller PD, Pannacciulli N, Malouf-Sierra J et al (2020) Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int 31(1):181\u2013191. https:\/\/doi.org\/10.1007\/s00198-019-05233-x","journal-title":"Osteoporos Int"},{"issue":"8","key":"6863_CR12","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","volume":"8","author":"DM Black","year":"2020","unstructured":"Black DM, Bauer DC, Vittinghoff E et al (2020) Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes Endocrinol 8(8):672\u2013682. https:\/\/doi.org\/10.1016\/S2213-8587(20)30159-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"6863_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY et al (2019) Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. J Bone Miner Res 34(4):632\u2013642. https:\/\/doi.org\/10.1002\/jbmr.3641","journal-title":"J Bone Miner Res"},{"issue":"3","key":"6863_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s00198-020-05732-2","volume":"32","author":"AR Zullo","year":"2021","unstructured":"Zullo AR, Lee Y, Lary C et al (2021) Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study. Osteoporos Int 32(3):565\u2013573. https:\/\/doi.org\/10.1007\/s00198-020-05732-2","journal-title":"Osteoporos Int"},{"issue":"4","key":"6863_CR15","doi-asserted-by":"publisher","first-page":"e192416","DOI":"10.1001\/jamanetworkopen.2019.2416","volume":"2","author":"AB Pedersen","year":"2019","unstructured":"Pedersen AB, Heide-J\u00f8rgensen U, S\u00f8rensen HT et al (2019) Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment within 3 Years of Initiation. JAMA Netw Open 2(4):e192416. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2416","journal-title":"JAMA Netw Open"},{"issue":"3","key":"6863_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/jbmr.3019","volume":"32","author":"NK Choi","year":"2017","unstructured":"Choi NK, Solomon DH, Tsacogianis TN et al (2017) Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res 32(3):611\u2013617. https:\/\/doi.org\/10.1002\/jbmr.3019","journal-title":"J Bone Miner Res"},{"issue":"2","key":"6863_CR17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/jbmr.4472","volume":"37","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber J, Lehmann D, Burkhard J-P et al (2022) Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis. J Bone Miner Res 37(2):340\u2013348. https:\/\/doi.org\/10.1002\/jbmr.4472","journal-title":"J Bone Miner Res"},{"issue":"10","key":"6863_CR18","doi-asserted-by":"publisher","first-page":"e10681","DOI":"10.1002\/jbm4.10681","volume":"6","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber J, Bonel H, Lehmann D et al (2022) Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy \u2013 A Registry-Based Cohort Study. JBMR plus 6(10):e10681. https:\/\/doi.org\/10.1002\/jbm4.10681","journal-title":"JBMR plus"},{"issue":"9","key":"6863_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C et al (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137\u20131148. https:\/\/doi.org\/10.1002\/jbmr.5650080915","journal-title":"J Bone Miner Res"},{"issue":"18","key":"6863_CR20","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/nejmoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med 357(18):1799\u20131809. https:\/\/doi.org\/10.1056\/nejmoa074941","journal-title":"N Engl J Med"},{"issue":"18","key":"6863_CR21","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/nejmoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med 356(18):1809\u20131822. https:\/\/doi.org\/10.1056\/nejmoa067312","journal-title":"N Engl J Med"},{"issue":"11","key":"6863_CR22","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: The fracture intervention trial. J Clin Endocrinol Metab 85(11):4118\u20134124. https:\/\/doi.org\/10.1210\/jcem.85.11.6953","journal-title":"J Clin Endocrinol Metab"},{"issue":"9041","key":"6863_CR23","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/s0140-6736(96)07088-2","volume":"348","author":"DM Black","year":"1996","unstructured":"Black DM, Cummings SR, Krapf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535\u201341. https:\/\/doi.org\/10.1016\/s0140-6736(96)07088-2","journal-title":"Lancet"},{"issue":"11","key":"6863_CR24","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.eprac.2021.06.015","volume":"27","author":"SG Albert","year":"2021","unstructured":"Albert SG, Wood E (2021) Meta-Analysis of Clinical Fracture Risk Reduction of Antiosteoporosis Drugs: Direct and Indirect Comparisons and Meta-Regressions. Endocr Pract 27(11):1082\u20131092. https:\/\/doi.org\/10.1016\/j.eprac.2021.06.015","journal-title":"Endocr Pract"},{"key":"6863_CR25","doi-asserted-by":"publisher","first-page":"1759720X2211050","DOI":"10.1177\/1759720X221105009","volume":"14","author":"G Adami","year":"2022","unstructured":"Adami G, Gavioli I, Rossini M et al (2022) Real-life short-term effectiveness of anti-osteoporotic treatments: a longitudinal cohort study. Ther Adv Musculoskeletal Dis 14:1759720X221105009. https:\/\/doi.org\/10.1177\/1759720X221105009","journal-title":"Ther Adv Musculoskeletal Dis"},{"key":"6863_CR26","doi-asserted-by":"publisher","first-page":"e068033","DOI":"10.1136\/bmj-2021-068033","volume":"381","author":"MN H\u00e4ndel","year":"2023","unstructured":"H\u00e4ndel MN, Cardoso I, von B\u00fclow C et al (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. 381:e068033. https:\/\/doi.org\/10.1136\/bmj-2021-068033","journal-title":"BMJ."},{"key":"6863_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30138-9","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6863_CR28","doi-asserted-by":"publisher","unstructured":"Black DM, Schwartz A, Ensrud K et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial long-term extension (FLEX): A randomized tria 296(24):2927\u201338.\u00a0https:\/\/doi.org\/10.1001\/jama.296.24.2927","DOI":"10.1001\/jama.296.24.2927"},{"key":"6863_CR29","doi-asserted-by":"publisher","unstructured":"Black DM, Reid I, Boonen S et al (2012) The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Min Res 27(2):243\u201354.\u00a0https:\/\/doi.org\/10.1002\/jbmr.1494","DOI":"10.1002\/jbmr.1494"},{"key":"6863_CR30","doi-asserted-by":"publisher","unstructured":"Bone HG, Hosking D, Devogelaer JP et al (2004) Ten years\u2019 experience with alendronate for osteoporosis in postmenopausal women. New Engl J Med 18;350(12):1189\u201399.\u00a0https:\/\/doi.org\/10.1056\/nejmoa030897","DOI":"10.1056\/nejmoa030897"},{"key":"6863_CR31","doi-asserted-by":"publisher","unstructured":"Ferrari S, Butler P, Kendler DL et al (2019) Further nonvertebral fracture reduction beyond 3 years for up to 10 years of denosumab treatment. J Clin Endocrinol Metabol 104(8):3450\u20133461.\u00a0https:\/\/doi.org\/10.1210\/jc.2019-00271","DOI":"10.1210\/jc.2019-00271"},{"key":"6863_CR32","doi-asserted-by":"publisher","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254\u20139. https:\/\/doi.org\/10.1136\/bmj.312.7041.1254","DOI":"10.1136\/bmj.312.7041.1254"},{"key":"6863_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115830","author":"J Everts-Graber","year":"2021","unstructured":"Everts-Graber J, Reichenbach S, Gahl B et al (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study. Bone 144:115830.\u00a0https:\/\/doi.org\/10.1016\/j.bone.2020.115830","journal-title":"Bone"},{"key":"6863_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4335","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O (2021) Fractures after denosumab discontinuation: a retrospective study of 797 Cases. J Bone Miner Res 36(9):1717\u20131728.\u00a0https:\/\/doi.org\/10.1002\/jbmr.4335","journal-title":"J Bone Miner Res"},{"key":"6863_CR35","doi-asserted-by":"publisher","unstructured":"Everts-Graber J, Reichenbach S, Gahl B et al (2022) Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a real-world setting. Bone 163:116498.  https:\/\/doi.org\/10.1016\/j.bone.2022.116498","DOI":"10.1016\/j.bone.2022.116498"},{"key":"6863_CR36","doi-asserted-by":"publisher","unstructured":"Fatoye F, Smith P, Gebrye T, Yeowell G (2019) Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open 9(4):e027049. https:\/\/doi.org\/10.1136\/bmjopen-2018-027049>","DOI":"10.1136\/bmjopen-2018-027049"},{"key":"6863_CR37","doi-asserted-by":"publisher","unstructured":"McGrath LJ, Spangler L, Curtis JR et al (2020) Using negative control outcomes to assess the comparability of treatment groups among women with osteoporosis in the United States. Pharmacoepidemiol Drug Saf 29(8):854\u2013863. https:\/\/doi.org\/10.1002\/pds.5037","DOI":"10.1002\/pds.5037"},{"key":"6863_CR38","doi-asserted-by":"publisher","unstructured":"Lems WF, Paccou J, Zhang J et al (2021) Vertebral fracture: epidemiology, impact and use of DXA vertebral fracture assessment in fracture liaison services. Osteoporosis Int 32(3):399\u2013411. https:\/\/doi.org\/10.1007\/s00198-020-05804-3","DOI":"10.1007\/s00198-020-05804-3"}],"updated-by":[{"DOI":"10.1007\/s00198-023-06887-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000}}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-023-06863-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-023-06863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:03:03Z","timestamp":1697418183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-023-06863-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["6863"],"URL":"https:\/\/doi.org\/10.1007\/s00198-023-06863-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"21 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00198-023-06887-4","URL":"https:\/\/doi.org\/10.1007\/s00198-023-06887-4","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JE, DL, BG, SR and TL have nothing to declare and no conflicts of interest. HB received consultancy fees from Novartis. HJH received occasional speaker\u2019s fees from Amgen, Sandoz, Eli Lilly and Labatec. HRZ received consultancy fees from Abbvie, Celgene, Amgen and Mylan\/Viatris. US received congress and travel expenses from Sandoz, Pfizer and Janssen Pharmaceutica, and consultancy fees from Novartis and Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}